Research Grade Sotigalimab

Research Grade Biosimilar

Tumor necrosis factor receptor superfamily member 5, B-cell surface antigen CD40, Bp50, CD40L receptor, TNFRSF5, CDw40, CD40

Blue-ice bags

The FDA has granted an orphan drug designation to sotigalimab (APX005M) as a potential therapeutic option for patients with soft tissue sarcoma, according to announcement from Apexigen Inc., the drug developer.
A novel, humanized monoclonal antibody, sotigalimab was designed stimulate antitumor immune response and to target CD40, which is a key co-stimulatory receptor that serves to activate innate and adaptive immune systems. When sotigalimab binds to CD40 on antigen-presenting cells, it induces a multifaceted immune response that brings several components of the immune system together to attack the cancer.

0.01M PBS, pH 7.4.

For research use only. Not suitable for clinical or therapeutic use.

1 mg/ml

Mammalian Cells